Platform Efficacy and Validation Risks: Absci's core business relies on its AI-powered drug discovery platform successfully identifying and optimizing novel drug candidates that are more likely to succeed in preclinical and clinical development, and a failure to consistently demonstrate this efficacy could harm its business.

Clinical Development and Approval Risks: Even if Absci's platform identifies promising drug candidates, these candidates, whether developed internally or by partners, must still undergo extensive and costly preclinical and clinical trials, which have a high failure rate, and ultimately secure regulatory approval.

Intense Competition Risks: The biopharmaceutical and AI drug discovery markets are highly competitive and rapidly evolving, with numerous established pharmaceutical companies, biotechnology firms, and other AI-driven platforms vying for talent, partnerships, and intellectual property.